Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients

Name: Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
License: Public Domain

Novartis Pharmaceuticals

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

hepatocellularcarcinoma

hepatocellular carcinoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 184867
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.